Romidepsin for cutaneous T-cell lymphoma. (December 2013)

• Record Type: Journal Article
• Authors: Prince, H Miles; Dickinson, Michael; Khot, Amit
• Is Part Of: Future oncology. Volume 9:Number 12(2013)
• Page Start: 1819
• Page End: 1827
• Publication Date: 2013-12
• Subjects: cutaneous -- depsipeptide -- histone deacetylase inhibitor -- lymphoma -- romidepsin; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.13.220
• Languages: English
• ISSNs: 1479-6694

Abstract

Cutaneous T-cell lymphomas are relatively rare lymphomas and the most common form is mycosis fungoides. Its rare leukemic variant is Sezary syndrome. Advanced-stage disease is typically treated with bexarotene (a retinoid), IFN-α or conventional chemotherapeutic agents, but relapses are inevitable. Histone deacetylase inhibitors that modify the epigenome are an attractive addition to the armamentarium. Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile.